AU2007302270B2 - Formulations comprising cyclic compounds - Google Patents

Formulations comprising cyclic compounds Download PDF

Info

Publication number
AU2007302270B2
AU2007302270B2 AU2007302270A AU2007302270A AU2007302270B2 AU 2007302270 B2 AU2007302270 B2 AU 2007302270B2 AU 2007302270 A AU2007302270 A AU 2007302270A AU 2007302270 A AU2007302270 A AU 2007302270A AU 2007302270 B2 AU2007302270 B2 AU 2007302270B2
Authority
AU
Australia
Prior art keywords
cyclic
protonated
compound
active agent
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2007302270A
Other languages
English (en)
Other versions
AU2007302270A1 (en
Inventor
Paolo Botti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Capsugel Belgium NV
Original Assignee
Capsugel Belgium NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Capsugel Belgium NV filed Critical Capsugel Belgium NV
Publication of AU2007302270A1 publication Critical patent/AU2007302270A1/en
Application granted granted Critical
Publication of AU2007302270B2 publication Critical patent/AU2007302270B2/en
Assigned to CAPSUGEL BELGIUM NV reassignment CAPSUGEL BELGIUM NV Request for Assignment Assignors: BOTTI, PAOLO
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D323/00—Heterocyclic compounds containing more than two oxygen atoms as the only ring hetero atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nanotechnology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2007302270A 2006-09-27 2007-09-27 Formulations comprising cyclic compounds Ceased AU2007302270B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06020286A EP1905454A1 (en) 2006-09-27 2006-09-27 Formulations comprising cyclic compounds
EP06020286.8 2006-09-27
PCT/EP2007/008442 WO2008037484A2 (en) 2006-09-27 2007-09-27 Formulations comprising cyclic compounds

Publications (2)

Publication Number Publication Date
AU2007302270A1 AU2007302270A1 (en) 2008-04-03
AU2007302270B2 true AU2007302270B2 (en) 2014-05-29

Family

ID=37728182

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007302270A Ceased AU2007302270B2 (en) 2006-09-27 2007-09-27 Formulations comprising cyclic compounds

Country Status (10)

Country Link
US (1) US8513188B2 (enExample)
EP (2) EP1905454A1 (enExample)
JP (1) JP5335677B2 (enExample)
CN (2) CN101557829A (enExample)
AU (1) AU2007302270B2 (enExample)
BR (1) BRPI0714761B8 (enExample)
CA (1) CA2664568C (enExample)
ES (1) ES2691736T3 (enExample)
IL (1) IL197760A (enExample)
WO (1) WO2008037484A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010323117B2 (en) 2009-11-25 2015-09-03 Capsugel Belgium Nv Mucosal delivery compositions comprising a peptide complexed with a crown comppound and/or a counter ion
EP2332929A1 (en) * 2009-11-25 2011-06-15 ArisGen SA Orthoester derivatives of crown ethers as carriers for pharmaceutical and diagnostic compositions
EP2526971A1 (en) * 2011-05-25 2012-11-28 ArisGen SA Mucosal delivery of drugs
CN102863358B (zh) * 2012-09-20 2014-02-12 华中农业大学 具有除草活性的化合物及其制备方法
EP3000811B1 (en) * 2014-09-24 2017-11-08 Friedrich-Alexander-Universität Erlangen-Nürnberg Crown Ether Complexes and Methods for Poducing the Same
US9937223B2 (en) 2015-01-30 2018-04-10 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9750785B2 (en) 2015-01-30 2017-09-05 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9687526B2 (en) 2015-01-30 2017-06-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9375478B1 (en) 2015-01-30 2016-06-28 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9925233B2 (en) 2015-01-30 2018-03-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9744209B2 (en) 2015-01-30 2017-08-29 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
CN108658264B (zh) * 2018-04-17 2021-05-25 唐山师范学院 多支化聚环氧琥珀酸衍生物阻垢缓蚀剂的制备及其应用方法
CN113527672B (zh) * 2020-03-30 2022-09-20 复旦大学 一种胍基衍生物及其基因递释系统
CN116178887B (zh) * 2023-02-16 2024-10-29 东华大学 一种可降解快递袋材料及其制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0021169A1 (de) * 1979-06-12 1981-01-07 Christian Dr. Prof. Birr Verfahren zur selektiven Bildung von Disulfidbrücken in Polypeptiden und die dabei erhaltenen Produkte als Wirkstoffe enthaltende Arzneimittel
US5023252A (en) * 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US6444226B1 (en) * 1999-06-29 2002-09-03 Pharmaceutical Discovery Corporation Purification and stabilization of peptide and protein pharmaceutical agents
JP2006232909A (ja) * 2005-02-23 2006-09-07 Tokai Univ 環状オリゴ乳酸

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474753A (en) * 1983-05-16 1984-10-02 Merck & Co., Inc. Topical drug delivery system utilizing thermosetting gels
AU6738487A (en) * 1985-12-04 1987-06-30 Hsieh, D. Transdermal delivery of drugs
CN1379771A (zh) * 1999-09-20 2002-11-13 天藤制药株式会社 环状乳酸齐聚物的制备方法
US7169814B2 (en) * 2001-12-11 2007-01-30 The Board Of Trustees Of The Leland Stanford Junior University Guanidinium transport reagents and conjugates

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0021169A1 (de) * 1979-06-12 1981-01-07 Christian Dr. Prof. Birr Verfahren zur selektiven Bildung von Disulfidbrücken in Polypeptiden und die dabei erhaltenen Produkte als Wirkstoffe enthaltende Arzneimittel
US5023252A (en) * 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US6444226B1 (en) * 1999-06-29 2002-09-03 Pharmaceutical Discovery Corporation Purification and stabilization of peptide and protein pharmaceutical agents
JP2006232909A (ja) * 2005-02-23 2006-09-07 Tokai Univ 環状オリゴ乳酸

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DARWISH I. A.: "The evaluation of crown ether based niosomes as cation containing and cation sensitive drug delivery systems" INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 159, 1997, pages 207213 *
DEGIM T.I. ET AL.: "Effect of ion complexants on the iontophoresis of salbutamol" INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 167, 1998, pages 229231, *
ELKA TOUITOU: "ENHANCEMENT OF INTESTINAL PEPTIDE ABSORPTION" JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM; NL, vol. 21, 1 July 1992, pages 139144, *
HAMACHER K ET AL: "EFFICIENT STEREOSPECIFIC SYNTHESIS OF NOCARRIERADDED 218FFLUORO2DEOXYDGLUCOSE USING AMINOPOLYETHER, SUPPORTED NUCLEOPHILIC SUBSTITUTION" JOURNAL OF NUCLEAR MEDICINE, SOCIETY OF NUCLEAR MEDICINE, V 27(2) 1986, pp 235-238 *
POPESCU D. A. ET AL.: REVUE ROUMAINE DE CHIMIE, vol. 43, no. 11, 1998, pages 10591064 *

Also Published As

Publication number Publication date
AU2007302270A1 (en) 2008-04-03
US20100137188A1 (en) 2010-06-03
CN101541346B (zh) 2014-07-02
EP2068934A2 (en) 2009-06-17
JP2010504934A (ja) 2010-02-18
CA2664568C (en) 2015-11-24
BRPI0714761B1 (pt) 2021-03-23
JP5335677B2 (ja) 2013-11-06
IL197760A (en) 2016-10-31
BRPI0714761A2 (pt) 2013-07-02
CN101557829A (zh) 2009-10-14
IL197760A0 (en) 2009-12-24
ES2691736T3 (es) 2018-11-28
WO2008037484A2 (en) 2008-04-03
CA2664568A1 (en) 2008-04-03
BRPI0714761B8 (pt) 2021-05-25
US8513188B2 (en) 2013-08-20
EP2068934B8 (en) 2018-09-05
WO2008037484A3 (en) 2008-12-18
CN101541346A (zh) 2009-09-23
EP2068934B1 (en) 2018-07-18
EP1905454A1 (en) 2008-04-02

Similar Documents

Publication Publication Date Title
AU2007302270B2 (en) Formulations comprising cyclic compounds
IL220003A (en) A drug release device
US20090311182A1 (en) Macromolecular Delivery Systems for Non-Invasive Imaging, Evaluation and Treatment of Arthritis and Other Inflammatory Diseases
Tai et al. A novel rapamycin-polymer conjugate based on a new poly (ethylene glycol) multiblock copolymer
KR20220134528A (ko) 치료 나노입자의 합성을 위한 방법 및 조성물
JP2019196399A (ja) 薬学的活性剤複合体、ポリマー複合体、ならびにこれらを伴う組成物及び方法
CA2783306C (en) Orthoester derivatives of crown ethers as carriers for pharmaceutical and diagnostic compositions
CN101312986A (zh) 生产修饰（多）肽的方法
CA3213233A1 (en) Synthetic peptide shuttle agent bioconjugates for intracellular cargo delivery
US20230181747A1 (en) Drug loaded peptide brush polymers
US8642555B2 (en) Prodrugs
US8247493B2 (en) Long acting formulation of biopharmaceutical
KR20240087591A (ko) 타겟 세포 내로 올리고뉴클레오티드를 전달하기 위한 펩타이드 기반 결합체를 포함하는 나노입자 및 이를 포함하는 약학적 조성물
Floyd III Synthesis and Evaluation of Dendritic Polymer Carriers for Chemotherapeutic and Imaging Applications
HK40031377A (en) Thioester prodrugs of macrocycles as inhibitors of histone deacetylases

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: CAPSUGEL BELGIUM NV

Free format text: FORMER OWNER(S): BOTTI, PAOLO

MK14 Patent ceased section 143(a) (annual fees not paid) or expired